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Abstract
Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a rare genetic disorder belonging to the group
of vacuolating leukodystrophies. It is characterized by megalencephaly, loss of motor functions, epilepsy, and mild
mental decline. In brain biopsies of MLC patients, vacuoles were observed in myelin and in astrocytes surrounding
blood vessels. There is no therapy for MLC patients, only supportive treatment. We show here a preclinical gene
therapy approach for MLC using the Mlc1 knock-out mouse. An adeno-associated virus coding for human MLC1
under the control of the glial fibrillary acidic protein promoter was injected in the cerebellar subarachnoid space of
Mlc1 knock-out and wild-type animals at 2 months of age, before the onset of the disease, as a preventive approach.
We also tested a therapeutic strategy by injecting the animals at 5 months, once the histopathological abnormalities
are starting, or at 15 months, when they have progressed to a more severe pathology. MLC1 expression in the
cerebellum restored the adhesion molecule GlialCAM and the chloride channel ClC-2 localization in Bergmann glia,
which both are mislocalized in Mlc1 knock-out model. More importantly, myelin vacuolation was extremely reduced
in treated mice at all ages and correlated with the amount of expressed MLC1 in Bergmann glia, indicating not only
the preventive potential of this strategy but also its therapeutic capacity. In summary, here we provide the first
therapeutic approach for patients affected with MLC. This work may have also implications to treat other diseases
affecting motor function such as ataxias.
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Megalencephalic leukoencephalopathy with subcortical cysts
(MLC) is a rare type of leukodystrophy characterized mainly
by myelin vacuolization and early onset of macrocephaly,
appearing at the first year of life [1]. Unsupported walking
ability is delayed in MLC1 patients and their gait is unstable
[2]. They develop progressive cerebellar ataxia and sometimes
spasticity and become wheelchair-dependent as teenagers.
Some patients also develop dystonia and athetosis. Mild cog-
nitive deterioration becomes apparent over the years and al-
most all children have occasional epileptic seizures, often in-
duced by minor head trauma [3]. Some patients have a more
severe clinical course, being able to walk without support for
only a short time or never achieve it [4]. Unfortunately, no
treatment is currently available for MLC patients.
MLC classic phenotype is inherited as autosomal recessive
trait and can be caused by mutations in two different genes.
The first gene described was MLC1 (MIM no. 605908) and
mutations in this gene cause MLC1-type disease in most pa-
tients [5]. The second gene involved in MLC classic pheno-
type is GLIALCAM (MIM no. 611642) [6, 7]. Mutations in
GLIALCAM can cause two different phenotypes: MLC2A
containing recessive mutations and exhibiting the same phe-
notype as patients carrying mutations in MLC1 gene [8], and
MLC2B inherited in a dominant form. Although MLC2B pa-
tients initially have the same symptoms as MLC1 or MLC2A
patients, its phenotype improves with time and finally they
show different symptoms ranging from a benign form of
MLC to macrocephaly and mental retardation with or without
autism [7, 9]. MLC1 encodes for a membrane protein also
called MLC1 that is mainly expressed in astrocytes surround-
ing blood vessels and the Bergmann glia in the cerebellum
[10, 11]. Different mutations have been described in MLC1,
which cause protein degradation [12]. GlialCAM is mainly
expressed in astrocytes co-localizing with MLC1, but also in
oligodendrocytes [7].
GlialCAM belongs to the immunoglobulin superfam-
ily and it is an adhesion molecule [13]. GlialCAM is
needed for MLC1 localization at astrocyte-astrocyte
junctions [6, 14]. However, GlialCAM has also been
described as an auxiliary subunit of the chloride channel
ClC-2 in astrocytes and oligodendrocytes [15], and it is
able to modify ClC-2 localization and different function-
al properties, such as rectification [16]. Lack of Mlc1
causes GlialCAM and ClC-2 mislocalization in astro-
cytes and oligodendrocytes, suggesting that trans inter-
actions formed between GlialCAM molecules expressed
in these two different cell types may exist [16, 17]. It
has been proposed that the mislocalization of GlialCAM
and ClC-2 in oligodendrocytes could contribute to the
appearance of vacuoles in myelin [16].
Recent studies performed withMlc1 and Glialcam knock-
out (KO) mice showed the development of macrocephaly and
progressive astrocyte and myelin vacuolization in these mice,
which were mainly restricted to the fiber tracts of the cerebel-
lum [16, 18, 19]. The vacuolization phenotype progressed
very slowly and the animals did not develop the motor or
cognitive abnormalities present in humans, thus they are pro-
posed as a model for early MLC phenotype. At 2 months of
age, Mlc1 and Glialcam KO animals showed very few vacu-
oles, which however, became evident at 4 months of age and
increased to extensive vacuolization in this area at 1 year of
age [16]. Additional loss of Glialcam in theMlc1 KO did not
increase the level of vacuolization [20]. It has been
suggested that vacuolization may be caused by defective
potassium brain dynamics and/or an alteration of cell
volume regulation [21–23].
The precise role of GlialCAM and MLC1 in glial cell ion/
water homeostasis is still completely unknown. MLC1 has
been related with different homeostatic processes such as the
activation of volume-regulated anion currents (VRACs) me-
diated by the LRRC8 proteins [24, 25], the regulation of the
activity of the ClC-2 chloride channel [16], the phosphoryla-
tion state of the EGF receptor [26], the regulation of the
endosomal pH [27], the response to osmotic stress in cooper-
ation with the TRPV4 channel [28], or the activity of the Na+/
K+-ATPase [29]. While still looking for the mechanisms of
action of these proteins, it is clear that the inactivity or absence
of MLC1 or GlialCAM proteins is responsible for the disease
phenotype. Thus, providing these proteins to the patient’s
brain, the normal phenotype may be restored.
In this regard, gene therapy is a promising therapeutic ap-
proach for chronic brain diseases since it permits to stably and
specifically deliver the missing gene to the target cells, over-
coming the difficulty of crossing the blood-brain barrier.
Among the available gene delivery vectors, adeno-associated
virus (AAV) vectors have several features that make them
attractive for brain gene transfer: they are less immunogenic
than human adenoviral vectors allowing for long-term trans-
gene expression as recently reported after 15 years of CNS
gene transfer in a non-human primate model [30]; they are
replication-defective in the absence of helper virus; the wild-
type AAV infections are not pathogenic and the vectors do not
contain viral genes. Among the AAV serotypes used as gene
transfer vectors in preclinical studies, AAV9 and AAVrh10 are
the serotypes presenting greater transduction capacity and
broader range of cell-type specific tropism, particularly in
the CNS. The use of AAVrh10, a non-human serotype, may
avoid the neutralization by anti-AAV immune factors present
in human sera after natural AAV infections, although cross-
reactivity with anti-AAV2, the most common AAV serotype,
may still interfere in the therapeutic outcome [31]. Moreover,
AAVrh10 is able to transduce glial cells, while AAV9 seems to
be more specific for neurons [32].
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Particular cell tropism can be efficiently accomplished by
combining different AAV serotypes, cell-specific promoters,
and different routes of administration, avoiding the non-
specific secondary effects caused by conventional pharmacolo-
gy. MLC1 gene encodes a protein mainly expressed in glial
cells of the adult human brain, such as astrocytes or
Bergmann glia with the highest expression in the cerebellum.
Glial fibrillary acidic protein (GFAP) is expressed in astrocytes
and its promoter has been used to drive exogenous proteins
specifically in this cell type in transgenic animals or using viral
vectors [33, 34]. Here, we have used AAVrh10 virus containing
a GFAP promoter to express human MLC1 in the astrocytes of
the cerebellum of Mlc1−/− mice at adult stages. We tested dif-
ferent routes of administration and doses to demonstrate that it
is possible to restore the localization of GlialCAM and ClC-2 in
Bergmann glia after AAV-mediated MLC1 expression specifi-
cally in astrocytes and more importantly, to rescue the vacuola-
tion phenotype inMlc1 KO, which may have potential as ther-
apeutic gene therapy strategy for MLC patients.
Materials and Methods
Animals
Mlc1 KO animals (Mlc1−/−) were generated as described pre-
viously [16]. KO and wild-type (WT) mice were housed at the
Animal Facilities of the IDIBELL, under standard conditions
(food and water ad lib, 22 ± 2 °C, 12 h light:dark starting at
08:00), until they were 6 or 12 months old. Experiments and
necropsies were performed in the Central Animal Facilities of
the Universitat Autònoma de Barcelona. This study was car-
ried out in strict accordance with the current National regula-
tions (Generalitat de Catalunya Decret 214/97 30th July) and
with the aim to reduce the number of animals used. The
Committees on the Ethics of Animal Facilities of IDIBELL
and the Universitat Autònoma de Barcelona approved all pro-
cedures described in this study (protocols numbers: DAAM
9073 and CEEAH 2945).
Viral Vector Generation, Production, and Purification
AAVrh10 vectors (null, GFAP-GFP and GFAP-MLC1, with
an HA epitope—in bold—AYDRYPYDVPDYAMPTL
added at the N-terminal region of MLC1 [11]) were produced,
purified, and manipulated in the biosafety level 2 facilities of
the Vector Production UAB-VHIR Joint Unit (www.
viralvector.eu) at the Universitat Autònoma Barcelona,
Spain. Briefly, vectors were generated using the triple
transfection system in HEK293 cells of the expression
plasmid (GFAP-GFP or GFAP-MLC1), Reprh10Cap2
plasmid containing AAV genes, and pXX6 plasmid
containing adenoviral genes needed as helper virus [35].
After 48 h, AAV vectors were harvested, treated with
benzonase, purified in an iodixanol gradient, and titrated
using the Picogreen system [36]. Quantification was
calculated as viral genomes per milliliter (vg/ml). Control
AAVrh10 empty vectors (null) containing only regulatory se-
quences were used as control.
In Vivo Administration of AAV Vectors
Mice were anesthetized by intraperitoneal injection of keta-
mine (10 mg/kg of body weight; Imalgene 500; Rhone-
Merieux, Lyon-Vénissieux, France) and xylazine (1 mg/kg
of body weight; Rompun; Bayer, Leverkusen, Germany).
We injected 5 × 1010 vg of each vector by different routes of
administration. Intrathecal administration was performed at
the lumbar region as previously described [37]. Briefly, after
lateral spine exposure by paravertebral muscle dissection,
10 μl of viral vectors was slowly injected into the CSF
through a 33-gauge needle and a Hamilton syringe between
L3 and L4 lumbar vertebrae. Appropriate access to the intra-
thecal space was confirmed by tail movement. The needle
remained at the injection site for one additional minute after
which muscle and skin were sutured. For intracranial admin-
istration, animals were mounted onto a stereotactic frame
( D a v i d K o p f I n s t r u m e n t s , T u j u n g a , C A ) .
Intracerebroventricular administration into the third ventricle
was performed at the appropriate coordinates according to The
Mouse Brain Atlas [38] (ML 1 mm, RC 0.34 mm, DV
2.5 mm) and 5 μl of the vector was administered with an
ultramicropump (World Precision Instruments, Sarasota, FL)
at a rate of 0.5 μl/min. The needle was slowly withdrawn after
additional 5 min. Intracerebellar (ICB) administration was
performed in three different ways: ICB into the white matter
(ICBWM, 3μl), ICB into themolecular layer (ICBML, 3 μl),
and ICB in the subarachnoid space (ICB SB, 5 μl). The deliv-
ery rate was 0.4 μl/min for intraparenchymal injections and
0.2 μl/min for subarachnoid administration. Coordinates for
ICB WM are 0 mm, − 6.24 mm, and 2.5 mm; for ICB ML
0 mm, − 7 mm, and − 1.2 mm; and for IBC SB 0 mm, − 7 mm,
and − 0.6 mm (bregma, lateral and depth, respectively). The num-
ber of animals injected with each virus, their genotype and gender
is listed in Supplementary Table 1.
Immunofluorescence and Histologic Analysis
Anesthetized animals were perfused with phosphate buffer,
followed by 4% paraformaldehyde in phosphate buffer. Half
brain was embedded with paraffin and the other half was
cryoprotected and embedded in Tissue-Tek® O.C.T™
Compound (Sakura FineTechnical Co, Tokyo, Japan). Ten-
micrometer-thick sections of sagittal sections were blocked and
incubated with primary antibodies overnight at 4 °C. Antibodies
against MLC1, GlialCAM, and ClC2 raised in rabbits were
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previously described [7, 12, 15]. The following concentrations
were used: Anti-MLC1 (1:50), anti-GlialCAM (1:50), anti-ClC-
2 (1:100), and anti-GFAP (1:200, Dako, Glostrup, Denmark).
Sections were then incubated with the following secondary anti-
bodies: Alexa Fluor goat anti-rabbit 568, goat anti-mouse 568,
and goat anti-rabbit 488 (1:200; all from Invitrogen, Carlsbad,
CA). Finally, they were counterstained with Hoescht stain solu-
tion (Sigma-Aldrich) for nuclei labeling, and they were mounted
in Fluoromount (Sigma-Aldrich). Images were acquired using an
epifluorescence or a confocal microscope (Leica TCS-SP2
AOBS; Leica Microsystems GmbH, Heidelberg, Germany).
The half brain embedded in paraffin was 4-μm-thick sectioned
and stained with hematoxylin-eosin and analyzed under bright-
field microscope. Morphometric quantification of the number
and size of the total number of vacuoles in the white matter
was performed in two consecutive slides 40 μm apart, using
Image J and Ilastik software [39]. Results were represented as
percentage of vacuolated area compared to the total white matter
area of each section or as number of vacuoles grouped in 3
different sizes: smaller than 300 μm, from 300 to 500 μm, and
larger than 500 μm.
Transmission Electron Microscopic Analysis
Cerebellar fragments of 1 mm3 were fixed in 2.5% glutaral-
dehyde and 2% paraformaldehyde for 2 h at 4 °C. After wash-
ing in cold phosphate buffer, samples were post-fixed in 1%
osmium tetroxide, dehydrated through a graded acetone se-
ries, and embedded in epoxy resin. Ultrathin sections (70 nm)
from resin blocks were stained using lead citrate and 2% ura-
nyl acetate followed by examination in a transmission electron
microscope (H-7000; Hitachi Ltd., Tokyo, Japan).
Western Blot
Some animals were euthanized without perfusion. Half cere-
bellum was homogenized in membrane extraction buffer
(PBS 1 ×, HEPES 25 mM, EDTA 4 mM, sucrose 250 mM)
and protease inhibitor cocktail (Millipore, Burlington, MA)
and after discarding tissue debris by centrifugation at 4000g,
cell membranes were obtained by ultracentrifugation at
100,000g. Protein concentration was determined by BCA
Protein Assay (Pierce, Rockford, IL), and 20 μg of proteins
were separated on 10% sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (Bio-Rad, Hercules, CA).
Polyvinylidene fluoride membranes were incubated with pri-
mary antibodies: rabbit anti-human MLC1 (1:1000; [12]) and
rabbit anti-GAPDH (1:1000; no. 14C10, Cell Signaling) and
secondary antibody anti-rabbit conjugated to horseradish per-
oxidase (1:2000; DakoCytomation, Glostrup, Denmark) com-
bined with western blotting detection reagent (WESTAR ETA
C Ultra 2.0; Cyanagen, Bologna, Italy) according to the man-
ufacturer’s instructions.
Quantitative PCR
Total RNA was extracted from the tissue samples using the
QIAzol Lysis Reagent (Qiagen, Hilden, Germany), quantified
on a NanoDrop spectrophotometer (Thermo Scientific,
Waltham, MA), and reverse transcribed into cDNA with
iScript cDNA Synthesis Kit (Bio-Rad). Gene-specific primers
used for the quantitative PCR analysis were huMLC FW:
TCGAGGTAATCGCAGGCATC ; h uMLC Rv :
AGGACCTCCACCAGACACTT; m36B4 Fwd :
ATGGGTACAAGCGCGTCCTG; and m36B4 Rv:
AGCCGCAAATGCAGATGGAT. Gene-specific mRNA
analysis was performed by SYBR green real-time PCR using
the MyiQ5 real-time PCR detection system (Bio-Rad).
Quantification relative to murine 36B4 controls was calculat-
ed using the Pfaffl method [40].
Statistics
Values are represented as mean ± SEM. Statistical analyses
using Student’s t test for qPCR, omnibus analysis by one-way
analysis of variance with Tukey post hoc tests, and multiple t
test for each individual size were performed for vacuole size
quantification. Differences were considered statistically sig-
nificant if p < 0.05.
Results
Cerebellar Administration in the Subarachnoid Space
Is the most Efficient Route to Transduce Bergmann
Glia
Recent studies performed with Mlc1 KO mice showed that
they might represent a model of MLC disease at early stages
of the disorder, with vacuoles located mainly in cerebellar
fiber tracts [16, 18, 19]. Thus, we decided to target the cere-
bellum of Mlc1 KO mice as a proof of principle for a gene
therapy strategy for MLC. Transduction of the cerebellum is
challenging compared to other brain areas. Therefore, we test-
ed several routes of administration using an AAV vector cod-
ing for green fluorescent protein (GFP) as a reporter gene,
under the regulation of the GFAP promoter, specific for astro-
cytes (AAV-GFAP-GFP; Fig. 1A).
Animals (n = 3 per condition) were injected by lumbar in-
trathecal puncture (IT, 10 μl), intracerebroventricularly (ICV,
5 μl), or intracerebellarly (ICB) with 5 × 1010 vg of AAV-
GFAP-GFP. This later administration was addressed by three
different ways, directly in the white matter (WM; 3 μl), or in
the molecular layer (ML; 3 μl) or into the CSF in the sub-
arachnoid space (SB; 5 μl) (Fig. 1B). We also tested different
delivery speeds, since it has been suggested that the cerebel-
lum could be better transduced by infusing the viruses at low
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speed [41]. When animals were administered by lumbar intra-
thecal injection, GFP expression was observed in the cerebel-
lar white matter but not in the Bergmann glia tracts in the
molecular layer (Fig. 1C). By ICV administration, we only
detected GFP signal in the contiguous areas of the third ven-
tricle. Finally, ICBWM administration efficiently reached the
white matter but the vector did not diffuse to the Bergmann
glia. Although ICBML achieved Bergmann glia transduction,
we found that subarachnoid administration of the vector at the
cerebellar area (ICB SB) was the most efficient route, achiev-
ing h igh t ransduc t ion in the whole cerebe l lum
(Supplementary Fig. 1A), both in the white matter and in the
Bergmann glia (Fig. 1C, ICB SB), although colocalization
with MLC1 was not evident in wild-type animals due to the
strong GFP signal that masked MLC1 immunofluorescence
(Supplementary Fig. 1B).
Subarachnoid Administration in the Cerebellum
of the AAV-GFAP-MLC Vector in Mlc1 KO Animals
Recovers the Expression of MLC1 in Bergmann Glia
A biodistribution study demonstrated that the AAV-GFAP-
GFP transduction pattern observed in WT animals replicated
in Mlc1 KO mice (n = 2; Fig. 2a). Moreover, when we
substituted GFP by human MLC1 in the AAV vector, MLC1
expression was evident in Bergmann glia in KO animals
injected at 2 months of age and analyzed 4 weeks later, as
demonstrated by immunohistochemistry (n = 2, Fig. 2b–d).
Expression in the cerebellum was also corroborated by whole
cerebellum quantitative PCR and by Western blot from cere-
bellar membrane extracts (Supplementary Fig. 2A and B,
respectively). In the Western blot, we observed two bands, a
lower strong band present only in WTanimals, corresponding
to the endogenous MLC1, and an upper fainter band, found
only in treated animals and compatible with humanMLC1 (as
it is tagged with a hemagglutinin (HA) epitope).
We initially tested three escalating doses of AAV-GFAP-
MLC1: 5 × 109, 2.5 × 1010, and 5 × 1010 vg/mouse. Two-
month-old Mlc1 KO animals (n = 3 per group/dose) were
treated before the histopathological symptoms appeared and
subsequently analyzed at 8 months of age. Comparing paraf-
fin sections stained with hematoxylin-eosin and consecutive
sections immunolabeled with anti-MLC1 antibody, we ob-
served a correlation between the expression of the transgene
and the degree of correction of the white matter vacuolation. A
complete correction was detected in the medial area with the
Fig. 1 Intracerebellar administration in the subarachnoid space is the
most efficient route to transduce Bergmann glia. (A) Scheme of the viral
construct containing GFP as reporter gene under the regulation of the
GFAP promoter. (B) Representation of the five administration routes
tested in this study. (C) Images were taken using a fluorescence micro-
scope and showed direct GFP fluorescence in the cerebellum of WT
animals injected with the AAV-GFAP-GFP by lumbar intrathecal (IT)
administration, by intracerebroventricular (ICV) injection, and by intra
cerebellar delivery in the white matter (ICB WM), in the molecular layer
(ICB ML), or in the subarachnoid space (ICB SB). Scale bar: 100 μm
Cerebellar Astrocyte Transduction as Gene Therapy for Megalencephalic Leukoencephalopathy
highest dose of viral vector (Fig. 2B, a), which allowedMLC1
expression along the Bergmann glia (Fig. 2B, b). In contrast,
many vacuoles were still present with the intermediate dose
(Fig. 2B, c), correlating with lower amount of MLC1 expres-
sion (Fig. 2B, d). Finally, no differences compared to untreat-
edMlc1KO animals were observed with the lowest dose (Fig.
2B, e), which was not enough to detect MLC1 expression in
the transduced animals (Fig. 2B, f).
AAV-null was used as control inMlc1KO andWTmice (n=
3/genotype). As an additional control, we analyzed WT animals
injected with AAV-GFAP-MLC1. We did not observe any detri-
mental effect (measured as an increase in vacuolization, data not
Fig. 2 (A) Subarachnoid
administration in the cerebellum
of the AAV-GFAP-MLC1 vector
in Mlc1 KO animals recovers the
expression of MLC1 in
Bergmann glia. (a) GFP expres-
sion in Bergmann glia in the cer-
ebellum of Mlc1 KO animals
injected with AAV-GFAP-GFP
vector, in green, colocalizes with
GFAP astrocytic marker (in red).
(b) Undetectable MLC1 expres-
sion (in green) in Mlc1 KO ani-
mals injected with the AAV-null
vector. GFAP is shown in red. (c)
Human MLC1 signal, in green, is
detected in Bergmann glia stained
in red by GFAP marker after
AAV-GFAP-MLC1 administra-
tion (scale bar, 50 μm). (d) Inset
magnification from c, showing
colocalization between MLC1
and GFAP immunoreactivity
(scale bar 25 μm). Hoescht co-
staining for nuclei is in blue. (B)
Correlation between AAV-
mediated MLC1 levels and white
matter vacuolation. Hematoxylin
and eosin staining (left) and con-
secutive slices with MLC1 im-
munohistochemistry (in green,
right) of the cerebellum from ani-
mals injected with different doses
of vector. There is a direct corre-
lation between the amount of vi-
rus, the immunoreactivity of
MLC1 in Bergmann glia, and the
number of vacuoles in the white
matter of the cerebella. Scale bar:




shown), contrary towhat has been reported in a transgenic animal
overexpressing MLC1 [42], suggesting that only supra-
physiological levels of MLC1 are deleterious.
MLC1 Administration in Young Animals Prevents
the Development of MLC Disease
Considering this preliminary data, we designed a thera-
peutic study to analyze the potential of our strategy to
prevent, treat, or even revert the effects of MLC1 defi-
ciency as schematized in Fig. 3. For that purpose, we
injected AAV-GFAP-MLC1 (Fig. 3A) at three different
stages of the disease. First, at 2 months of age, previous
to disease onset which is around 16 weeks, as a pre-
ventive strategy. Second, we injected 5-month-old ani-
mals, just after cerebellar vacuolation was evident in
this mouse model, as a corrective strategy (early
therapeutic approach, Fig. 3B). Both groups of animals
were analyzed at 8 months of age, when cerebellar
vacuolization has reached its maximum level. And third,
we were also interested to check the potential of our
strategy to revert the effects of the disease at 15 months
of age, 1 year after the development of the first patho-
logical hallmarks of the disease. These animals were
analyzed 3 months later, at the age of 18 months (late
therapeutic strategy; Fig. 3B).
We compared 3 groups of animals treated at 2 months
of age, as a preventive strategy: Mlc1 KO injected with
a null vector, Mlc1 KO injected with the therapeutic
vector carrying the human MLC1 transgene, and as a
control, WT animals injected also with the null vector.
At 8 months of age, immunohistochemistry for MLC1
showed a substantial increase in their protein signal at
Bergmann glia in the treated mice (Fig. 4c) compared to
Mlc1 KO (Fig. 4b), which was very similar to WT
animals (n = 4; Fig. 4a). Moreover, the mislocalization
of GlialCAM and ClC-2 (Fig. 4e and Fig. 4h,
respectively) was rescued after treatment with the
AAV-MLC1 (Fig. 4f for GlialCAM and Fig. 4i for
ClC-2), achieving similar levels to WT animals (Fig.
4d, g). Analogous results were reached in the white
matter of treated animals (not shown). We hypothesize
that this rescue is not due to mRNA stabilization be-
cause it was previously shown that KO of Mlc1 or
GlialCAM does not affect mRNA levels of GlialCAM
or MLC1, respectively; similarly, ClC-2 mRNA concen-
tration is also unchanged in both KO mice [16]. Our
results demonstrated that MLC1 expression is necessary
and sufficient to recover the organization of GlialCAM
and ClC-2 in Mlc1 KO mice. The stabilization of ClC-2
and GlialCAM by the reintroduction of MLC1 confirms
that the ternary complex formed by the three proteins is more
stable at the plasma membrane, as previously seen in vitro and
in vivo [22, 43]. Importantly, restoration of the normal pattern
of these three proteins induced also a reduction in the percent-
age of myelin vacuolization in the cerebellum of 8-month-old
animals treated at 2 months of age, when compared to untreat-
ed animals (Fig. 4j–l). Thus, restoring expression of MLC1 in
the brain with AAV vectors is a preventive treatment in the
MLC preclinical mouse model.
Fig. 3 Experimental design for the gene therapy MLC approach. (A)
Scheme of the viral construct containing human MLC1 as therapeutic
gene, under the regulation of the GFAP promoter. (B) Three preclinical
studies were designed, the first as a preventive strategy where young non-
affectedMlc1KOwere treated at 2 months and euthanized 6months later;
and two therapeutic studies with animals treated at 5 (early) and
15 months (late) and analyzed 3 months later
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Astrocyte-Directed MLC1 Gene Therapy Significantly
Reduces White Matter Vacuoles in the Cerebellum
of 5- and 15-Month-Old KO Animals, Demonstrating
its Therapeutic Potential
To evaluate the therapeutic potential of this strategy, we treat-
ed young but already leukodystrophic Mlc1 KO animals (at
5 months of age) and followed their recovery up to 3 months
after treatment, as a more translational approach. As shown
previously, MLC1 expression (Fig. 5a–c) was evident in the
Bergman glia of WT and KO-treated animals and correlated
with GlialCAM (Fig. 5d–f) and ClC-2 (Fig. 5g–i) expression
in the same area. Remarkably, hematoxylin and eosin staining
revealed an important reduction in the number and size of the
myelin vacuoles in KO-treated animals (Fig. 5j–l).
Finally, to evaluate the potential of revertingMLC pathology
with gene therapy, we treated 15-month-oldMlc1 KO animals,
when the disease has already progressed to the most severe
pathology, and we analyzed them at 18 months of age.
Results are shown in Fig. 6, with very similar histological data
as for animals treated before histopathology appeared (2months
of age) or just after it became evident (5-month-old).
Quantification and Ultrastructure Analysis
of the Leukodystrophy in MLC1 Mice
To monitor the efficiency of our treatment, we performed an
extensive quantification analysis of the vacuolization pheno-
type. At a first step, wemeasured the percentage of vacuolated
area in 8- or 18-month-old treated animals which was not
statistically different from WT mice, while important differ-
ences were detected when compared to untreated Mlc1 KO
mice (Fig. 7A). Importantly, quantification of the percentage
of vacuolated area was similar between animals injected as
before (2 months) or just after histopathology was evident
(5 months) and analyzed at the same age.
Fig. 4 HumanMLC1 transgene expression before disease onset prevents
the development of cerebellum vacuolation inMlc1KO animals. (a, d, g)
Confocal microscope representative images from WT animals (injected
with an AAV-null; n = 4) showing MLC1 (a, green), GlialCAM (d, red),
or ClC-2 (g, magenta) immunoreactivity. (b, e, h) Confocal microscope
representative images from untreatedMlc1 KO animals (injected with an
AAV-Null; n = 3) labeled for MLC1 (b, green), GlialCAM (e, red), or
ClC-2 (h, magenta). (c, f, i) Immunofluorescence representative images
from AAV-GFAP-MLC1-injected KO animals (n = 4) labeled for MLC1
(c, green), GlialCAM (f, red), or Clc-2 (i, magenta). Absence of MLC1
andmislocalization of GlialCAMandClC-2 proteins inMlc1KOanimals
is evident, and localization of both proteins is restored by the administra-
tion of the AAV-GFAP-MLC1 vector. (j, k, l) Representative bright-field
microscope images from hematoxylin-eosin staining of untreated WT (j),
untreatedMlc1 KO (k), or treatedMlc1 KO (l) animals showing a signif-
icant reduction of the myelin vacuolation in treated animals, similar to
WT. Scale bar: 50 μm in confocal microscopy images and 200 μm in
bright-field images
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In a second step, we analyzed the size and number of the
vacuoles in these sections. In all size ranges, statistically sig-
nificant differences were evident between WT and untreated
Mlc1 KO animals (Fig. 7B). Comparing treated and untreated
animals, statistically significant differences were also detected
for the three treatment groups and vacuole range (Fig. 7B).
Moreover, Mlc1 KO animals in the 8-month-old cohorts did
not show any significant differences compared to WT mice
and in the group of 18-month-old animals differences were
only detected in the smaller size vacuoles (p < 0.05) while
for sizes larger than 300 μm, late-treated animals were similar
to WT mice, reinforcing the therapeutic capacity of the treat-
ment (Fig. 7B).
Finally, we analyzed the ultrastructure of the cerebellar
white matter by transmission electron microscopy in 8-
month-old Mlc1 KO mice after 3 months of treatment (Fig.
7C, n = 2/group). While large vacuoles in myelin sheaths,
mainly affecting oligodendrocytes, extended through the cer-
ebellum in untreated mice (Fig. 7C, a and d), AAV-treated
animals showed similar ultrastructure to WT mice (Fig. 7C,
b and e vs. c and f). Altogether, this data demonstrate that our
strategy is able to revert the phenotype of MLC disease even
when it is well established.
Discussion
Despite MLC1 functions are still unknown, we demonstrate
here that by restoring MLC1 expression in the cerebellum of
Mlc1 KO mice, we can increase the protein levels and rescue
the correct localization of GlialCAM and ClC-2 proteins in the
Bergmann glia. More importantly, reestablishing the expres-
sion of MLC1 leads to a significant decrease of white matter
vacuolation, which is a hallmark ofMLC.Moreover, there is a
Fig. 5 Human MLC1 administration in disease-affected Mlc1 KO ani-
mals at 5 months of age reduces the vacuolation in cerebellar white
matter. (a, d, g) Representative images from WT animals (injected with
an AAV-Null; n = 4) showing MLC1 (a, green), GlialCAM (d, red), or
ClC-2 (g, magenta) immunofluorescence. (b, e, h) Representative fluo-
rescence images from untreatedMlc1KO animals (injected with an AAV-
null; n = 3) showing no immunoreactivity toMLC1 (b, green), GlialCAM
(e, red), or ClC-2 (h, magenta). (c, f, i) Representative images from AAV-
GFAP-MLC1-injected KO animals (n = 3) showing MLC1 (c, green),
GlialCAM (f, red), or ClC-2 immunoreactivity (i, magenta). Results in-
dicated a restoration of MLC1, GlialCAM, and ClC-2 localization by the
administration of the AAV-GFAP-MLC1 vector in 5-month-old animals
similarly to what was observed when animals were treated at 2 months of
age. (j, k, l) Representative images from hematoxylin-eosin staining in
paraffin sections ofWT (j), untreatedMlc1KO (k), or treatedMlc1KO (l)
animals show a significant reduction of the myelin vacuolation in treated
animals, as occurred with 2-month-old animals. Scale bar: 50 μm in
confocal microscopy images and 200 μm in bright-field images
Cerebellar Astrocyte Transduction as Gene Therapy for Megalencephalic Leukoencephalopathy
correlation between the expression of MLC1 and the number
of vacuoles after treatment, although we provide evidence that
low levels of MLC1 are enough to diminish the size and the
number of myelin vacuoles. This has major implications for
therapy for MLC patients, for which there is currently no cure.
We are able to restore MLC1 expression in the whole cerebel-
lum, both in Bergmann glia and in the white matter.
Interestingly, by correcting MLC1 levels in astrocytes, we
significantly reduced the size and number of vacuoles in oli-
godendrocytes in the white matter. This is probably
achieved to a certain extent due to the rescue of
GlialCAM location in oligodendrocytes and to the re-
covery of astrocytic homeostasis.
Gene therapy is a promising therapeutic approach for
chronic diseases with brain involvement, since it permits to
stably and specifically deliver the missing gene to the target
cells, overcoming the difficulty of crossing the blood-brain
barrier. The main advantage of the proposed gene therapy
strategy is that, by using a particular serotype of AAV vector,
a glial-specific promoter, and different routes of administra-
tion, we can specifically target astrocytes and avoid non-
Fig. 6 MLC1 administration in long-term affected Mlc1 KO mice also
reverts the vacuolization phenotype. (a, d, g) Representative images from
WT animals (injected with AAV-Null; n = 3) showing MLC1 (a, green),
GlialCAM (d, red), or ClC-2 (g, magenta). (b, e, h) Representative im-
munohistochemistry of samples from untreated Mlc1 KO animals
(injected with AAV-null; n = 4) showing MLC1 (b, green), GlialCAM
(e, red), or ClC-2 (h, magenta) immunoreactivity. (c, f, i) Representative
images from AAV-GFAP-MLC1-injected Mlc1 KO animals (n = 5)
showing MLC1 (c, green), GlialCAM (f, red), or ClC-2 (i, magenta). (j,
k, l) Hematoxylin-eosin staining in paraffin sections of untreated WT (j),
Mlc1 KO (k), or treated Mlc1 KO (l) animals. Scale bar: 50 μm in con-
focal microscopy images and 200 μm in bright-field images
Fig. 7 Quantificative and qualitative study of vacuoles in the whitematter
of the cerebellum. (A) Percentage of vacuolation was quantified in cere-
bellar sections separated by 40 μm. Values are expressed as percentage of
vacuolated area compared to the total area of the white matter in each
section in 8- and 18-month-old animals, WT, treated, or untreated Mlc1
KO mice (n = 3 per age and treatment). One-way ANOVA and Tukey
post hoc analysis for each time point are depicted on the graph (*p < 0.05;
**p < 0.01). (B) Histogram distribution of vacuoles size (in μm2) in WT,
treated, or untreatedMlc1 KO mice at 8 and 18 months of age (n = 3 per
age and treatment). Statistics: omnibus analysis by one-way ANOVAwith
Tukey post hoc tests showed statistical significant differences between
WT and KO-null and between treated and untreated KO groups but not
between WT and treated cohorts. Multiple t tests for the different size
range vacuoles show statistically significant differences for all groups and
sizes compared with untreated KO (*p < 0.05; **p < 0.01; ***p < 0.001)
or between small vacuoles from 18-month-old treated vs WT mice
($p < 0.05). (C) Ultrastructural analyses of myelin vacuolization by trans-
mission electronic microscopy. Myelin vacuolization at two different
magnifications showing large vacuoles of aberrant myelin in Mlc1 KO
mice (a, d), and normal ultrastructure inMlc1KOmice treated with AAV-
GFAP-MLC1 (b, e) and WT animals (c, f). ax, axon; o, oligodendrocyte
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specific effects. Recently, gene therapy in a mouse model of
Pelizaeus-Merzbacher-like disease using AAV vectors ex-
pressing Connexin 47 in oligodendrocytes resulted in signifi-
cant phenotypic improvement [44]. Similarly, AAV express-
ing aspartoacylase in astrocytes were able to rescue the lethal
disease phenotype of Canavan disease–affected mice [45].
Mlc1 KO mice, unlike patients with MLC, do not display
any motor or cognitive phenotypes, nor do they show changes
in the transmission of myelin action potentials [46]. Thus, we
used this mouse model at later stages as representative of the
MLC disease at its earliest stages, since the mouse
myelination pattern is different from that of humans [19].
Very recently, hindlimb clasping when suspended from the
tail was reported in a different mouse model of MLC as a sign
of neurological abnormality, co-occurring with seizures or in-
creased seizure susceptibility in mouse models for other neu-
rological diseases [21]. We evaluated hindlimb clasping in our
mouse model but however no clear abnormality was detected
in untreated KO mice which hindlimbs were indistinctly fully
spread or fully drown to the abdomen. Thus, no validation of
this test could be established for our mouse model.
Expression studies performed during human development
suggested that in humans, MLC1 role might be very important
at early stages, where protein levels are higher [19]. These
results, together with the analysis of a heterozygous knock-in
mice [16], explain why patients carrying dominant mutations in
GLIALCAM have a remitting phenotype: they still have some
functionalMLC1 localized in astrocyte-astrocyte junctions, and
this reduced amount could be enough to perform its function in
adulthood, but not in earlier ages. According to this hypothesis,
it could be possible to improve the phenotype of MLC patients,
even at adult stages. We have demonstrated this hypothesis in
long-term affected animals, when the disease has progressed to
the most severe phenotype and where we could achieve similar
levels of correction than in animals treated as before disease
onset or at early stages of the disease.
A recent study in MLC1-overexpressing transgenic mice
reported that supra-physiological levels of MLC1 (ten times
higher than WT) resulted in white matter cavitation in the
brain starting already at postnatal day 7 and continuing up to
day 28 [42]. In our hands, no deleterious effects of MLC
overexpression were detected in WT animals, suggesting that
the levels ofMLC1 protein expressed in the cerebellum of KO
mice, much lower than WT levels, were sufficient to achieve
correction, as expected for a recessive disease, but not detri-
mental in the WT mice. Nevertheless, an inducible promoter
might be used to increase safety.
Translating this strategy to human MLC patients will be
challenging but astrocyte-targeted gene therapy with MLC1
has a great potential not only as a preventive treatment, but
more importantly for its therapeutic capacity. Global CNS
transduction may be necessary since the affected areas are
wider than those in the KO mouse, where only the cerebellum
is affected. Other routes of administration may be explored like
intraventricular or intrathecal administration or its combination
with subarachnoid delivery or even convection-enhanced deliv-
ery which could allow direct, homogeneous, targeted perfusion
of different CNS areas while bypassing the blood-brain barrier
[47]. On the other hand, our strategy could open the possibility
to treat other diseases affecting the cerebellum.
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